Neoparin

Leaflet attached to the packaging: patient information

Neoparin, 2000 IU (20 mg)/0.2 ml, solution for injection
Neoparin, 4000 IU (40 mg)/0.4 ml, solution for injection
Neoparin, 6000 IU (60 mg)/0.6 ml, solution for injection
Neoparin, 8000 IU (80 mg)/0.8 ml, solution for injection
Neoparin, 10,000 IU (100 mg)/1 ml, solution for injection
Enoxaparin sodium

Read the leaflet carefully before using the medicine, as it contains important information for the patient.

• Keep this leaflet, you may need to read it again.
• If you have any further questions, ask your doctor, pharmacist, or nurse.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
• If you experience any side effects, including those not listed in this leaflet, tell your doctor or pharmacist. See section 4.

Table of contents of the leaflet

• 1. What is Neoparin and what is it used for
• 2. Important information before using Neoparin
• 3. How to use Neoparin
• 4. Possible side effects
• 5. How to store Neoparin
• 6. Contents of the pack and other information

1. What is Neoparin and what is it used for

Neoparin contains the active substance enoxaparin sodium, which is a low molecular weight heparin (LMWH).
Neoparin works in two ways.

• 1) It prevents the growth of existing blood clots. This helps the body to dissolve existing blood clots, making them harmless.
• 2) It prevents the formation of new blood clots in the patient's blood.

Neoparin can be used for:

• Treating blood clots that are already present in the patient's blood.
• Preventing the formation of blood clots in the patient's blood in the following situations:
• Before and after surgery
• During acute illness, when the patient has limited mobility
• In patients who have developed blood clots in the circulating blood due to cancer, to further prevent the formation of new blood clots
• In unstable angina (a condition in which the heart receives insufficient blood)
• After a heart attack
• Preventing the formation of clots in dialyzer tubes (used in patients with severe kidney function disorders).

2. Important information before using Neoparin

When not to use Neoparin

• If the patient is allergic to enoxaparin sodium or any of the other ingredients of this medicine (listed in section 6). Symptoms of an allergic reaction may include: rash, difficulty swallowing or breathing, swelling of the lips, face, throat, or tongue.
• If the patient has been diagnosed with an allergy to heparin or other low molecular weight heparins, such as nadroparin, tinzaparin, or dalteparin.
• If the patient has been diagnosed with a reaction to heparin that caused a significant decrease in the number of blood cells responsible for blood clotting (platelets) - a reaction known as heparin-induced thrombocytopenia - within the last 100 days or if there are antibodies against enoxaparin in the patient's blood.
• If the patient has severe bleeding or a medical condition associated with an increased risk of bleeding (e.g., stomach ulcers, recent brain or eye surgery), including recent hemorrhagic stroke.
• If the patient is using Neoparin to treat blood clots and spinal or epidural anesthesia or lumbar puncture is planned within 24 hours.

Warnings and precautions

Neoparin should not be used interchangeably with other low molecular weight heparins. This is because they are not exactly the same, differ in activity, and have different instructions for use.
Before starting Neoparin, discuss with your doctor or pharmacist if:

• the patient has ever had a reaction to heparin that caused a significant decrease in the number of platelets
• spinal or epidural anesthesia or lumbar puncture is planned (see "Surgical procedures and anesthetics"): an appropriate time interval between Neoparin administration and this procedure should be considered
• the patient has a heart valve replacement
• the patient has endocarditis (infection of the membrane lining the heart)
• the patient has had stomach ulcers
• the patient has recently had a brain stroke
• the patient has high blood pressure
• the patient has diabetes or has problems with blood vessels in the eyes caused by diabetes (so-called diabetic retinopathy)
• the patient has recently had eye or brain surgery
• the patient is elderly (over 65 years), especially if they are over 75 years old
• the patient has kidney disease
• the patient has liver disease
• the patient is underweight or overweight
• the patient has an increased level of potassium in the blood (which can be checked with a blood test)
• the patient is currently taking medications that may cause bleeding (see below "Neoparin and other medicines")

Before starting Neoparin and periodically during its use, the patient may undergo a blood test to check the number of platelets and potassium levels in the blood.

Neoparin and other medicines

Tell your doctor or pharmacist about all medicines you are taking, have recently taken, or plan to take.

• Warfarin - a medicine used to thin the blood
• Aspirin (also known as acetylsalicylic acid or ASA), clopidogrel, or other medicines used to prevent blood clots (see also section 3 "Change of anticoagulant treatment")
• Dextrans - used as a blood substitute
• Ibuprofen, diclofenac, ketorolac, or other non-steroidal anti-inflammatory medicines used to treat pain and swelling in arthritis and other conditions
• Prednisolone, dexamethasone, or other medicines used to treat asthma, rheumatoid arthritis, and other conditions
• Medicines that increase potassium levels in the blood, such as potassium salts, diuretics, and certain heart medicines.

Surgical procedures and anesthetics

If the patient is scheduled for a lumbar puncture or surgery under spinal or epidural anesthesia, they should inform their doctor that they are taking Neoparin. See "When not to use Neoparin". Additionally, the patient should inform their doctor if they have any spinal problems or if they have had spinal surgery.

Pregnancy and breastfeeding

If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before using this medicine.
In pregnant women with a mechanical heart valve, there may be an increased risk of blood clots. The doctor should discuss this with the patient.
Women who are breastfeeding or plan to breastfeed should consult their doctor before using this medicine.

Driving and using machines

Neoparin does not affect the ability to drive or use machines.
The doctor should document the trade name and batch number of the product used.

3. How to use Neoparin

This medicine should always be used exactly as prescribed by your doctor or pharmacist. If you are unsure, ask your doctor or pharmacist.

Administration of the medicine

• Neoparin will usually be administered to the patient by a doctor or nurse. This is because it requires injection.
• After returning home, the patient may need to continue using Neoparin and administer it themselves (see the administration instructions below).
• Neoparin is usually administered by subcutaneous injection.
• Neoparin may be administered intravenously in certain types of heart attack or after surgery.
• Neoparin may be introduced into the dialyzer tube returning blood from the body (into the so-called arterial line) at the start of the dialysis session.
• Neoparin must not be administered by intramuscular injection.

Dose of the medicine

• The doctor will decide what dose of Neoparin the patient should take. This depends on the reason for using the medicine.
• In patients with kidney disease, the patient may receive a lower dose of Neoparin.
• 1. Treatment of blood clots already present in the patient's blood
• The usual dose is 150 IU (1.5 mg) per kilogram of body weight once daily or 100 IU (1 mg) per kilogram of body weight twice daily.
• The doctor will decide how long the patient should receive Neoparin.
• 2. Prevention of blood clot formation in the patient's blood in the following situations:
• Surgical procedure or period of limited mobility due to illness
• The dose depends on the patient's risk of developing a blood clot. The patient will receive Neoparin at a dose of 2000 IU (20 mg) or 4000 IU (40 mg) per day.
• In the case of planned surgery, the first injection is usually performed 2 hours or 12 hours before the procedure.
• If the patient has limited mobility due to illness, they will usually receive Neoparin at a dose of 4000 IU (40 mg) per day.
• The doctor will decide how long the patient should receive Neoparin.
• After a heart attackNeoparin can be used in two different types of heart attack: ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI). The dose of Neoparin will depend on the patient's age and the type of heart attack they had.

NSTEMI:

• The usual dose is 100 IU (1 mg) per kilogram of body weight every 12 hours.
• The doctor will usually recommend that the patient also take aspirin (acetylsalicylic acid).
• The doctor will decide how long the patient should receive Neoparin.

STEMI in patients under 75 years of age:

• An initial dose of 3000 IU (30 mg) will be administered intravenously.
• Neoparin will also be administered subcutaneously. The usual dose is 100 IU (1 mg) per kilogram of body weight every 12 hours.
• The doctor will usually recommend that the patient also take aspirin (acetylsalicylic acid).
• The doctor will decide how long the patient should receive Neoparin.

STEMI in patients 75 years of age or older:

• The usual dose is 75 IU (0.75 mg) per kilogram of body weight every 12 hours.
• The maximum dose of Neoparin in the first two doses is 7500 IU (75 mg).
• The doctor will decide how long the patient should receive Neoparin.

Patient undergoing percutaneous coronary intervention (PCI):
Depending on when the last dose of Neoparin was administered, the doctor may decide to administer an additional dose of Neoparin before the PCI procedure. The medicine will be administered intravenously.

• 3. Prevention of blood clot formation in dialyzer tubes
• The usual dose is 100 IU (1 mg) per kilogram of body weight.
• Neoparin is injected into the tube returning blood from the body (into the so-called arterial line) at the start of the dialysis session. This dose is usually sufficient for a 4-hour dialysis session. However, if necessary, the doctor may administer an additional dose of 50 IU to 100 IU (0.5 to 1 mg) per kilogram of body weight.

Instructions for using the pre-filled syringe

How to administer Neoparin by yourself
If you can administer this medicine yourself, your doctor or nurse will show you how to do it.
Do not attempt to inject yourself without prior training.
If you are unsure what to do, consult your doctor or nurse immediately.
Before injecting Neoparin yourself

• Check the expiration date of the medicine. Do not use it if it has expired.
• Check if the pre-filled syringe is damaged and if the medicine is a clear solution. If not, use another pre-filled syringe.
• Do not use this medicine if you notice any changes in the appearance of the product.
• Make sure you know the planned dose of the medicine to be administered.
• Examine your abdomen to check if the last injection did not cause redness, skin discoloration, swelling, discharge, or persistent pain
• if so, consult your doctor or nurse.
• Decide where to inject the medicine. The medicine should be administered alternately on the left and right side of the abdomen. The medicine should be injected just under the skin on the abdomen, but not too close to the navel or any scar tissue (at least 5 cm away).
• The pre-filled syringe is for single use only.

Instructions for self-injecting Neoparin

• 1)Wash your hands and the injection site with water and soap. Dry.
• 2)Sit or lie down in a comfortable, relaxed position. Make sure the planned injection site is visible. It is ideal to use a recliner, armchair, or bed with pillows.
• 3)Choose a site on the right or left side of the abdomen. It should be at least 5 cm away from the navel towards the side.

Important:Do not inject the medicine into areas that are less than 5 cm away from the navel or around scars or bruises. The medicine should be injected alternately on the left and right side of the abdomen, changing sides each time.

• 4)Carefully remove the needle cap. The pre-filled syringe is pre-filled with the medicine and ready for use.

Do notpress the plunger before injecting the medicine to remove air bubbles.
This may cause loss of medicine. After removing the cap, do not allow the needle to come into contact with any object. This is to ensure the sterility of the needle.

• 5)Hold the pre-filled syringe (like a pencil) in the hand used for writing, and with the other hand gently pinch the cleaned area on the abdomen between the thumb and index finger, creating a skin fold.

Remember to hold the skin fold in this way throughout the injection.

• 6)Hold the pre-filled syringe so that the needle is pointing downwards (at a 90º angle). Insert the entire length of the needle into the skin fold.

• 7)Press the plunger with your finger. This will move the medicine into the fatty tissue on the abdomen. Remember to hold the skin fold throughout the injection.
• 8)Remove the needle by pulling it straight out.

To avoid bruising, do not rub the injection site after administration.

• 9)Dispose of the used pre-filled syringe.

Pre-filled syringes should not be disposed of in household waste bins.

How to administer Neoparin by yourself
The pre-filled syringe used by the patient may have a needle shield to prevent needle stick injury. If you can administer this medicine yourself, your doctor or nurse will show you how to do it.
Do not attempt to inject yourself without prior training. If you are unsure what to do, consult your doctor or nurse immediately.
Before injecting Neoparin yourself

• Check the expiration date of the medicine. Do not use it if it has expired.
• Check if the pre-filled syringe is damaged and if the medicine is a clear solution. If not, use another pre-filled syringe.
• Do not use this medicine if you notice any changes in the appearance of the product.
• Make sure you know the planned dose of the medicine to be administered.
• Examine your abdomen to check if the last injection did not cause redness, skin discoloration, swelling, discharge, or persistent pain
• if so, consult your doctor or nurse.
• Decide where to inject the medicine. The medicine should be administered alternately on the left and right side of the abdomen. The medicine should be injected just under the skin on the abdomen, but not too close to the navel or any scar tissue (at least 5 cm away).
• The pre-filled syringe is for single use only.

Instructions for self-injecting Neoparin

• 1)Wash your hands and the injection site with water and soap. Dry.
• 2)Sit or lie down in a comfortable, relaxed position. Make sure the planned injection site is visible. It is ideal to use a recliner, armchair, or bed with pillows.
• 3)Choose a site on the right or left side of the abdomen. It should be at least 5 cm away from the navel towards the side.

Important:Do not inject the medicine into areas that are less than 5 cm away from the navel or around scars or bruises. The medicine should be injected alternately on the left and right side of the abdomen, changing sides each time.

• 4)Carefully remove the needle cap. The pre-filled syringe is pre-filled with the medicine and ready for use.

Do notpress the plunger before injecting the medicine to remove air bubbles.
This may cause loss of medicine. After removing the cap, do not allow the needle to come into contact with any object. This is to ensure the sterility of the needle.

• 5)Hold the pre-filled syringe (like a pencil) in the hand used for writing, and with the other hand gently pinch the cleaned area on the abdomen between the thumb and index finger, creating a skin fold.

Remember to hold the skin fold in this way throughout the injection.

• 6)Hold the pre-filled syringe so that the needle is pointing downwards (at a 90º angle). Insert the entire length of the needle into the skin fold.

• 7)Press the plunger with your finger. This will move the medicine into the fatty tissue on the abdomen. Remember to hold the skin fold throughout the injection.
• 8)Remove the needle by pulling it straight out. Do not release the pressure on the plunger!

To avoid bruising, do not rub the injection site after administration.

• 9)Press the plunger firmly. The needle shield, which is a plastic cylinder, will automatically slide over the needle, completely covering it.

• 10)Dispose of the used pre-filled syringe.

Pre-filled syringes should not be disposed of in household waste bins.

Change of anticoagulant treatment

• Change from Neoparin to vitamin K antagonist medicines (e.g., warfarin)The doctor will recommend blood tests to determine the INR and based on this, will inform the patient when to stop taking Neoparin.
• Change from vitamin K antagonist medicines (e.g., warfarin) to NeoparinThe patient should stop taking the vitamin K antagonist medicine. The doctor will recommend blood tests to determine the INR and based on this, will inform the patient when to start taking Neoparin.
• Change from Neoparin to direct oral anticoagulantsThe patient should stop taking Neoparin. Then, the patient should start taking the direct oral anticoagulant 0-2 hours before the scheduled time of the next Neoparin injection. The patient should then continue taking the oral anticoagulant as usual.
• Change from direct oral anticoagulant to NeoparinThe patient should stop taking the direct oral anticoagulant. Neoparin treatment can be started 12 hours after the last dose of the direct oral anticoagulant.

Use in children and adolescents

The safety and efficacy of Neoparin in children and adolescents have not been established.

Overdose of Neoparin

If the patient thinks they have used too much or too little Neoparin, they should immediately inform their doctor, nurse, or pharmacist, even if they do not notice any problems.
In case of accidental injection or ingestion of Neoparin by a child, immediate medical attention should be sought at the hospital emergency department.

Missed dose of Neoparin

If a dose is missed, it should be taken as soon as possible. Do not take a double dose to make up for a missed dose. Keeping a diary helps to ensure that no dose is missed.

Stopping Neoparin treatment

If you have any further questions about using this medicine, ask your doctor, pharmacist, or nurse.
It is important to continue injecting Neoparin until the doctor recommends stopping it. If treatment is stopped, a blood clot may form, which can be very dangerous.

4. Possible side effects

Like all medicines, Neoparin can cause side effects, although not everybody gets them.
As with other similar medicines (used to reduce blood clotting), Neoparin can cause bleeding, which can be life-threatening. In some cases, bleeding may not be immediately visible.
If you experience any bleeding that does not stop on its own, as well as signs of excessive bleeding (severe weakness, fatigue, paleness, dizziness, headaches, or unexplained sweating), consult your doctor immediately.
The doctor may decide to monitor the patient more closely or change the medicine.
Stop using Neoparin and consult your doctor or nurse immediately if you experience symptoms of a severe allergic reaction (such as difficulty breathing, swelling of the lips, face, throat, or tongue).
If you experience any of the following symptoms, stop using Neoparin and seek medical attention immediately:

• A red, scaly, widespread rash with thickening of the skin and blisters, accompanied by fever. These symptoms usually appear at the beginning of treatment (acute generalized exanthematous pustulosis).

Consult your doctor immediately:

• If the patient experiences any signs of a blood clot, such as:
• cramping pain, redness, increased warmth, or swelling in one leg - these are symptoms of deep vein thrombosis
• shortness of breath, chest pain, fainting, or coughing up blood - these are symptoms of pulmonary embolism
• If the patient experiences painful rash or dark red spots under the skin that do not disappear when pressed. The doctor may order blood tests to check the platelet count.

List of possible side effects:

Very common (may affect more than 1 in 10 people)

• Bleeding.
• Increased liver enzyme activity.

Common (may affect up to 1 in 10 people)

• Increased tendency to bruise. This may be due to a decrease in platelet count.
• Pink spots on the skin. These changes are more likely to occur at the injection sites of Neoparin.
• Hives.
• Itchy, red skin.
• Bruising or pain at the injection site.
• Decreased red blood cell count.
• Increased platelet count.
• Headache.

Uncommon (may affect up to 1 in 100 people)

• Sudden severe headache. This may be a sign of bleeding into the brain.
• Tenderness and swelling in the abdomen. This may be a sign of bleeding into the stomach.
• Large, red, irregularly-shaped skin changes with blisters or without blisters.
• Skin irritation (local irritation).
• The patient may notice yellowing of the skin or eyes and darker urine. This may indicate liver disease.

Rare (may affect up to 1 in 1000 people)

• Severe allergic reaction. Symptoms of such a reaction may include: rash, difficulty swallowing or breathing, swelling of the lips, face, throat, or tongue.
• Increased potassium levels in the blood. This is more likely in people with kidney disease or diabetes. The doctor may check this with a blood test.
• Increased eosinophil count in the blood. The doctor may check this with a blood test.
• Hair loss.
• Osteoporosis (a condition in which bones are more prone to fractures) after long-term use of the medicine.
• Numbness, tingling, and muscle weakness (especially in the lower part of the body) after lumbar puncture or spinal or epidural anesthesia.
• Loss of control over the bladder or bowels (a condition in which the patient is unable to control when they need to go to the toilet).
• Hardening or a lump at the injection site.

Reporting side effects

If you experience any side effects, including those not listed in this leaflet, tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Jerozolimskie Avenue 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Neoparin

Store at a temperature below 25°C. The medicine can also be stored in a refrigerator (2°C - 8°C) for no longer than 1 month. Do not freeze.
Keep the medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the carton and pre-filled syringe after EXP. The expiration date refers to the last day of the month stated.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the pack and other information

What Neoparin contains

• The active substance is enoxaparin sodium

Neoparin, 2000 IU (20 mg)/0.2 ml:One pre-filled syringe of 0.2 ml contains 2000 IU (20 mg) of enoxaparin sodium.
Neoparin, 4000 IU (40 mg)/0.4 ml:One pre-filled syringe of 0.4 ml contains 4000 IU (40 mg) of enoxaparin sodium.
Neoparin, 6000 IU (60 mg)/0.6 ml:One pre-filled syringe of 0.6 ml contains 6000 IU (60 mg) of enoxaparin sodium.
Neoparin, 8000 IU (80 mg)/0.8 ml:One pre-filled syringe of 0.8 ml contains 8000 IU (80 mg) of enoxaparin sodium.
Neoparin, 10,000 IU (100 mg)/1 ml:One pre-filled syringe of 1 ml contains 10,000 IU (100 mg) of enoxaparin sodium.

• The other ingredients are: water for injections.

What Neoparin looks like and contents of the pack

Pre-filled syringes with a needle, with or without a needle shield, in blisters, in a cardboard box.
2 or 10 pre-filled syringes with a needle of 0.2 ml
2 or 10 pre-filled syringes with a needle of 0.4 ml
2 or 10 pre-filled syringes with a needle of 0.6 ml
2 or 10 pre-filled syringes with a needle of 0.8 ml
2 or 10 pre-filled syringes with a needle of 1.0 ml
Not all pack sizes may be marketed.

Marketing authorization holder and importer

SciencePharma Limited
Chełmska Street 30/34, 00-725 Warsaw, Poland

Date of last revision of the leaflet: December 2023

Other sources of information

Detailed information about this medicine is available on the website of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products http://www.urpl.gov.pl/pl